• Naringenin Modulates ER Stress to Counter Insulin Resistance

  2026-07-03

  This study demonstrates that naringenin alleviates HCV-induced insulin resistance by attenuating endoplasmic reticulum (ER) stress, particularly the IRE1α/XBP1 pathway, in hepatocytes and mouse liver. The findings highlight a mechanistic link between viral infection, ER stress, and metabolic dysfunction, offering new avenues for therapeutic intervention.

• HOXC8 Suppresses Pyroptosis via Caspase-1 Repression in NSCL

  2026-07-02

  This study reveals that the transcription factor HOXC8 inhibits pyroptotic cell death in non-small cell lung carcinoma (NSCLC) by suppressing caspase-1 expression through recruitment of HDAC1/2 to the CASP1 promoter. These findings clarify a specific epigenetic mechanism by which HOXC8 promotes NSCLC cell survival, offering new entry points for targeted research on caspase signaling pathways and inflammation-linked tumorigenesis.

• ECL Chemiluminescent Substrate Detection Kit: HRP Workflow M

  2026-07-02

  Unlock hypersensitive HRP chemiluminescence for reliable immunoblotting detection of low-abundance proteins. This guide translates breakthrough research into practical workflows, troubleshooting, and optimized protocols with the ECL Chemiluminescent Substrate Detection Kit (Hypersensitive).

• Mifepristone (RU486): From Receptor Antagonism to Ferroptosi

  2026-07-01

  Explore the advanced molecular mechanisms and translational assay guidance for Mifepristone (RU486), a potent progesterone receptor antagonist. This article uniquely connects ferroptosis, cell cycle regulation, and reproductive signaling, providing practical insight for oncology and reproductive biology researchers.

• Epoxomicin in Viral Immunity: Proteasome Inhibition Beyond P

  2026-07-01

  Explore how Epoxomicin, a potent proteasome inhibitor, enables advanced research at the intersection of ubiquitin-proteasome pathway dynamics and viral immune evasion. This article unveils new applications in inflammation and necroptosis modeling, distinguishing itself from prior protocol- and workflow-focused guides.

• EphA2 Synthetic Lethality in MYC-Driven Triple-Negative Brea

  2026-06-30

  This study establishes a chemogenetic screening approach that identifies EphA2 inhibition as a synthetic lethal vulnerability in MYC-driven triple-negative breast cancer (TNBC). The findings highlight a promising, MYC-selective therapeutic strategy that operates independently of p53 status and is validated both in vitro and in TNBC xenograft models.

• Tunicamycin (SKU B7417): Precision N-Glycosylation Inhibitio

  2026-06-30

  This article provides scenario-driven guidance for researchers leveraging Tunicamycin (SKU B7417) as an N-glycosylation inhibitor in cell viability, proliferation, and inflammation assays. It addresses experimental design, protocol optimization, and data interpretation, highlighting the product's reproducibility and validated performance. Readers will find practical, literature-backed insights to enhance assay reliability and translational impact.

• (5Z)-7-Oxozeaenol: Illuminating TAK1–SQSTM1 Crosstalk in Inf

  2026-06-29

  (5Z)-7-Oxozeaenol is a highly selective TAK1 inhibitor uniquely suited to dissecting the interplay between kinase signaling and cellular stress responses. This in-depth article explores how (5Z)-7-Oxozeaenol enables mechanistic insights into SQSTM1-mediated feedback loops, advancing inflammation research beyond standard protocols.

• Fluorescein TSA Kit: Precision Signal Amplification in Neuro

  2026-06-29

  Explore how the Fluorescein TSA Fluorescence System Kit empowers ultrasensitive, spatially precise detection in neurobiological research. Delve into advanced applications and novel assay strategies that set this cornerstone guide apart.

• H-Aggregated NIR-II Fluorophores Enable Enhanced Tumor PTT

  2026-06-28

  Yu et al. developed a lipid nanosystem that delivers H-aggregated NIR-II fluorophores and carboplatin to tumor cell membranes, achieving targeted photothermal and chemotherapeutic synergy. This work addresses longstanding inefficiencies in organic small-molecule fluorophore-based tumor therapies and enhances the stability and efficacy of photothermal conversion in vivo.

• Coumestrol: Phytoestrogen Estrogen Receptor Antagonist in RA

  2026-06-27

  Coumestrol unlocks new dimensions for rheumatoid arthritis research by enabling finely tuned modulation of estrogen and nuclear receptor pathways. Its dual role as a selective estrogen receptor modulator and ferroptosis inducer makes it indispensable for cell-based studies targeting inflammation and synoviocyte proliferation.

• Indole Analogue Tc3: Pyroptosis Induction in Hepatic Carcino

  2026-06-26

  A recent study identifies Tc3, a novel indole-thiazolidinedione analogue, as a potent inducer of gasdermin E-mediated pyroptosis in hepatic carcinoma. The research demonstrates Tc3's efficacy in inhibiting tumor growth, enhancing immune cell infiltration, and improving the outcomes of combination therapies, highlighting its translational promise for challenging liver cancers.

• Tunicamycin as a Precision Tool for UPR Modulation and Cadmi

  2026-06-26

  Explore how Tunicamycin serves as a potent N-glycosylation inhibitor to dissect endoplasmic reticulum stress and its pivotal role in adaptive cellular responses, including cadmium resistance. This article uniquely bridges mechanistic insights from recent research with advanced, protocol-ready guidance.

• Nuclear-Targeted Peptide Nanorods and DMXAA Amplify STING Im

  2026-06-25

  Wu et al. present a nanomedicine strategy that combines nuclear-targeted peptide nanorods with the STING agonist DMXAA to induce localized DNA damage and potentiate innate anti-tumor immunity. This approach achieves robust activation of NK and T cells, enhancing tumor suppression and offering a precise tool for cancer immunotherapy research.

• Exendin-4: Mechanistic Insights and Translational Impact in

  2026-06-25

  Explore the multifaceted mechanisms of Exendin-4, a leading GLP-1 receptor agonist, and discover how its advanced applications drive innovation in type 2 diabetes research. This article delivers novel scientific perspectives and practical guidance beyond standard assay workflows.

11410 records 2/761 page Previous Next 12345 下5页 Last page